Wednesday, April 21, 2021 10:49:14 PM
Scroll down to the Acknowledgements section and find Northwest:
Acknowledgments
The authors thank the Society for Neuro-Oncology and their Staff for their tremendous contributions to the arrangements and coordination for the meeting.
Authorship statement. Writing and editing of the original manuscript by all authors. Revision by P.C., F.C., P.B.W., M.G., M.P., R.M.P., and H.O. We declare no parts of the manuscript have been previously published or submitted concurrently to any other journal and all co-authors have read and approved of its submission to this journal.
Conflicts of interest statement. Y.C.: an inventor on a patent related to the TGF-beta CAR technology discussed in the publication. E.A.C.: currently an advisor to Advantagene Inc., Alcyone Biosciences, Insightec, Inc., DNAtrix Inc., Immunomic Therapeutics, Sangamo Therapeutics, Seneca Therapeutics and has equity interest in DNAtrix, Immunomic Therapeutics, Seneca Therapeutics; he has also advised Oncorus, Merck, Tocagen, Ziopharm, Stemgen, NanoTx., Ziopharm Oncology, Cerebral Therapeutics, Genenta. Merck, Janssen, Karcinolysis, Shanghai Biotech. He has received research support from NIH, US Department of Defense, American Brain Tumor Association, National Brain Tumor Society, Alliance for Cancer Gene Therapy, Neurosurgical Research Education Foundation, Advantagene, NewLink Genetics, and Amgen. He also is a named inventor on patents related to oncolytic HSV1 and noncoding RNAs. R.A.D.: founder, director, and/or advisor of Tvardi Therapeutics, Nirogy Therapeutics, Stellanova Therapeutics, Asylia Therapeutics, and Sporos Bioventures. B.M.E.: For Profits—Medicenna—Paid Consultant—Significant (>$20k), MedQIA, LLC—Paid Consultant, Ad Board, Neosoma—Paid Consultant, Agios Pharmaceuticals—Paid Consultant, Ad Board, Siemens—Paid Consultant, Research Grant, Ad Board, Janssen Pharmaceuticals—Research Grant, Imaging Endpoints—Paid Consultant, Kazia/Novogen—Paid Consultant, Ad Board, VBL—Research Grant, NW Biopharmaceuticals—Paid Consultant, Ad Board, Oncoceutics Inc.—Consultant, BeiGene—Consultant, BBI—Consultant, Tocagen—Consultant; Non-Profits: Global Coalition for Adaptive Research (GCAR)—Consultant, NIH/NCI Cancer Imaging Steering Committee—Paid Consultant, National Brain Tumor Society—Research Grant, American Cancer Society—Research Grant. J.R.H.: the founder and board member of the following companies: Indi Molecular, PACT Pharma, Isoplexis, and Sofie Biosciences. A.B.H.: serves on the scientific advisory board of Caris Life Science and WCG Oncology Board, he received licensing fees from Celldex Therapeutics and DNAtrix, received clinical trial funding from Merck and Celularity, and received study drug from Moleculin. N.K.: consultant for Abintus Bio, GenVivo, and SillaJen Biotherapeutics. L.M.L.: Consultant fees—JW Creagene, InSightec, Arbor Pharmaceuticals; **Research grants to institution—Northwest Biotherapeutics, Merck. M.L.:** Research Support—Arbor, BMS, Accuray, DNAtrix, Tocagen, Biohaven, Kyrin-Kyowa; Consultant—Tocagen, SQZ Technologies, VBI; CMO—Egret Therapeutics, Patent, Focused radiation + checkpoint inhibitors, Non-research Consultant – Stryker. E.W.N.: a co-founder, advisor, and shareholder of ImmunoScape Pte. Ltd. and an advisor for Neogene Therapeutics and Nanostring Technologies. H.O.: Consultant fees: Bristol-Myers Squibb, Agios Pharmaceuticals, Grant/Research support from: Agios Pharmaceuticals. Royalties as Inventor of: the H3.3K27M TCR, IL-13Ra2 (345-353:1A9V) peptide, and EGFRvIII-CAR for which an exclusive licensing agreement has been executed with Tmunity, Inc., Stemline, Inc., and Novartis Pharma, respectively. M.P.: reports non-financial support from Roche, personal fees and non-financial support from Bayer, personal fees from Novartis, personal fees from Apogenix, non-financial support from Pfizer, personal fees from Affiris outside the submitted work. In addition, M.P. has a patent EP2753315B1 licensed to Bayer, a patent EP2800580B1 issued, a patent US20180155403A1 pending, a patent US20180246118A1 pending, a patent US20170254803A1 pending, a patent WO2018146010A1 licensed to Bayer, a patent WO2019101643A1 licensed to Bayer, a patent WO2019101647A1 licensed to Bayer, a patent WO2019101641A1 licensed to Bayer, and a patent WO2019101642A1 licensed to Bayer. P.Y.W.: Research Support—Agios, Astra Zeneca/Medimmune, Beigene, Celgene, Eli Lily, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Oncoceutics, Vascular Biogenics, VBI Vaccines; Advisory Board—Agios, Astra Zeneca, Bayer, Boston Pharmaceuticals, Immunomic Therapeutics, Karyopharm, Kiyatec, Puma, Taiho, Vascular Biogenics, Deciphera, VBI Vaccines, Tocagen, Voyager, QED, Imvax, Elevate Bio; Speaker—Merck, Prime Oncology. All other authors declared none.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM